Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Donepezil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Donepezil and BMS-708163 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Donepezil | DRUG | Tablets, Oral, 5 mg, Once Daily, Days 1-28 |
| BMS-708163 | DRUG | Capsule, Oral, 125 mg, Once Daily, Days 15-28 |
Inclusion Criteria: * Healthy men and postmenopausal women Exclusion Criteria: * Medical History and Concurrent Diseases * Gastrointestinal disease * Gastrointestinal bleeding disorders * History of peptic ulcer disease * History of cholecystectomy * History of seizure disorder * History of asthm...
Top 20 of 24 competitors
Donepezil is a small molecule being studied for the treatment of Alzheimer Disease. It is currently in Phase 1 clinical development as an investigational drug. The therapeutic area is Neurology, and the developer is Bristol-Myers Squibb Company (BMY).
Donepezil is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The drug is a small molecule intended for Alzheimer Disease and is currently in Phase 1 clinical development.
Donepezil is in Phase 1 clinical development. It is an investigational drug for Alzheimer Disease and has not been approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently ongoing.
Donepezil has one completed clinical trial, NCT01042314, titled "Drug-Drug Interaction Study With Aricept® (Donepezil)". This Phase 1 study enrolled 18 participants with Alzheimer Disease in the United States. The trial was not randomized, double-blind, or controlled.
Yes, Donepezil is the same as Aricept. The clinical trial NCT01042314 is titled "Drug-Drug Interaction Study With Aricept® (Donepezil)", indicating that Aricept is a brand name for donepezil. The drug is being studied for Alzheimer Disease.